Related Experiment Video
Updated: Oct 18, 2025
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
419
Filgotinib as rheumatoid arthritis therapy
A Becciolini1, E Di Donato2, D Santilli2
1Department of Medicine, Internal Medicine and Rheumatology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy. beccio@yahoo.it.
Drugs of Today (Barcelona, Spain : 1998)
|September 29, 2021
Summary
Filgotinib, a selective JAK1 inhibitor, offers a new oral treatment option for rheumatoid arthritis (RA) patients who do not respond well to other therapies. Studies confirm its safety and effectiveness in managing RA symptoms.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune condition causing joint inflammation and disability.
- A significant portion of RA patients (up to 30%) show inadequate response or lose response to existing treatments like conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs).
- Janus kinase inhibitors (JAKis) represent a newer class of drugs for RA management.
Purpose of the Study:
- To evaluate the safety and efficacy of filgotinib, a selective JAK1 inhibitor, in treating rheumatoid arthritis (RA).
- To assess filgotinib's utility in RA patients with inadequate response to prior therapies.
Main Methods:
- Clinical trials (Phase II and III) were conducted to assess filgotinib.
- Studies included RA patients who were naive to DMARDs or had an insufficient response to csDMARDs and bDMARDs.
- Filgotinib was administered orally.
Main Results:
- Phase II and III studies demonstrated the safety and efficacy of filgotinib in RA patients.
- The drug showed positive outcomes in patients with varying treatment histories, including those new to DMARDs and those who had failed other treatments.
Conclusions:
- Filgotinib is an effective and safe oral treatment option for rheumatoid arthritis.
- It provides a valuable therapeutic alternative for RA patients with inadequate response to conventional and biologic therapies.
- Recommended dosages are 200 mg daily, with a reduced dose of 100 mg daily for patients over 75 or with moderate to severe renal impairment.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
259
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
259
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
287
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
287
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
240
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
240
01:29Inflammatory Bowel Disease IV: Pharmacological Management
242
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
242
01:29Drugs for Treatment of Ulcerative Colitis in IBD
269
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
269
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
284
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
284